Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020

被引:3
|
作者
Chen, Kun [1 ]
Jiang, Kehua [2 ]
Tang, Lannan [2 ]
Chen, Xiaolong [2 ]
Hu, Jianxin [2 ]
Sun, Fa [2 ]
机构
[1] Guizhou Prov Peoples Hosp, NHC Key Lab Pulm Immune Related Dis, Guiyang, Peoples R China
[2] Guizhou Prov Peoples Hosp, Dept Urol, Guiyang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
drug trials; prostate cancer; chemotherapy; gene-targeted; immunotherapy; IMMUNE-CHECKPOINT INHIBITORS; RADIOTHERAPY; STATISTICS;
D O I
10.3389/fonc.2021.647110
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The overall aging of the world population has contributed to the continuous upward trend in the incidence of prostate cancer (PC). Trials on PC therapy have been extensively performed, but no study has analyzed the overall trends and characteristics of these trials, especially for those carried out in China. This study aimed to provide insights on the future direction of drug development in PC, thus supplying essential supportive data for stakeholders, including researchers, patients, investors, clinicians, and pharmaceutical industry. The details of the clinical trials of drug therapies for PC during January 1, 2010, to January 1, 2020, were collected from Pharmaprojects. A total of 463 clinical trials on different therapies with 132 different drugs were completed. The long-acting endocrine therapy with few side effects, radiotherapy combined with immune checkpoint inhibitors, gene-targeted chemotherapeutics, and novel immunotherapeutic products changed the concept of PC treatment. In mainland China, 31 trials with 19 drugs have been completed in the 10 assessment years. China has initiated a few trials investigating a limited number of drug targets, centered in a markedly uneven geographical distribution of leading clinical trial units; hence, the development of PC drugs has a long way to go. Given the large patient pool, China deserves widespread attention for PC drug research and development. These findings might have a significant impact on scientific research and industrial investment.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] How to Conduct Clinical Trials of Personalized Cancer Therapies
    Clark-Garvey, Sean
    Milowsky, Matthew, I
    EUROPEAN UROLOGY FOCUS, 2022, 8 (03): : 667 - 669
  • [42] An update on clinical trials of targeted therapies in thyroid cancer
    Haraldsdottir, Sigurdis
    Shah, Manisha H.
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 (02): : 121 - 130
  • [43] Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review
    Li, Ning
    Huang, Hui-Yao
    Wu, Da-Wei
    Yang, Zhi-Min
    Wang, Jun
    Wang, Jian-Sheng
    Wang, Shu-Hang
    Fang, Hong
    Yu, Yue
    Bai, Ying
    Yan, Zhao
    Cao, Ye
    Jiang, Min
    Liu, Yan-Fei
    Li, Kun-Yan
    Xu, Bing-He
    Sun, Yan
    He, Jie
    LANCET ONCOLOGY, 2019, 20 (11): : E619 - E626
  • [44] Clinical trials for lung cancer in China
    Niu, Fei-Yu
    Zhong, Wen-Zhao
    Zhou, Qing
    Wu, Yi-Long
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (05) : 311 - 316
  • [45] Design of clinical trials on prostate cancer - Introduction
    Andersson, L
    UROLOGY, 1997, 49 (4A) : 1 - 2
  • [46] Clinical trials of immunotherapy for advanced prostate cancer
    Kuratsukuri, K
    Nishisaka, N
    Jones, RF
    Wang, CY
    Haas, GP
    UROLOGIC ONCOLOGY, 2000, 5 (06): : 265 - 273
  • [47] Prostate cancer gene therapy clinical trials
    Freytag, Svend O.
    Stricker, Hans
    Movsas, Benjamin
    Kim, Jae Ho
    MOLECULAR THERAPY, 2007, 15 (06) : 1042 - 1052
  • [48] Prostate Cancer Prevention: Concepts and Clinical Trials
    Hamilton, Zachary
    Parsons, J. Kellogg
    CURRENT UROLOGY REPORTS, 2016, 17 (04)
  • [49] Endpoints in prostate cancer clinical trials - Discussion
    Lubeck, DP
    Sartor, O
    Kantoff, PW
    Kelly, WK
    Carroll, PR
    UROLOGY, 2002, 60 (3A) : 107 - 108
  • [50] Prostate Cancer Prevention: Concepts and Clinical Trials
    Zachary Hamilton
    J. Kellogg Parsons
    Current Urology Reports, 2016, 17